Mid-term review of The National AIDS Programme 2011-15
October 2013
PLOS ONE | www.plosone.org
September 2014 | Volume 9 | Issue 9 | e103657
PLoS ONE 9(1): e87262. doi:10.1371/journal.pone.0087262
Euro Surveillance 2014;19(47):pii=20970, p.31-37
Evaluation report
January 2014
Presentation is current through November 21, 2014 and will be updated every Friday by 5pm. For the most up-to-date information, please visit www.cdc.gov/ebola.
*Presentation contains materials from CDC, MSF, and WHO
This document builds on the Background document prepared for the September 4-5, 2014 Consultation. It includes proposed elements to consider during the development of a framework to assist decision-making at global and national level.
The aim of the document is to assist Member States and releva...nt partners in their discussions to identify the best approaches to ensure the accelerated evaluation and use of available or near-term therapies and vaccines for the treatment and prevention of EVD. The document calls for a coordinated effort by the international community to remove unnecessary obstacles towards this goal.
more
Infectious Diseases of Poverty 2014, 3:42
http://www.idpjournal.com/content/3/1/42
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more
The IMCI chart booklet is for use by doctors, nurses and other health professionals who see young infants and children less than five years old. It facilitates the use of the IMCI case management process in practice and describes a series of all the case management steps in a form of IMCI charts.
...These charts show the sequence of steps and provide information for performing them. The IMCI chart booklet should be used by all health professionals providing care to sick children to help them apply the IMCI case management guidelines. Health professionals should always use the chart booklet for easy reference.The chart booklet is divided into two main parts because clinical signs in sick young infants and older children are somewhat different and because case management procedures also differ between these age groups.
Sick child aged 2 months to 5 years
This part contains all the necessary clinical algorithms, information and instructions on how to provide care to sick children aged 2 months to 5 years.
Sick young infant aged up to 2 months
This part includes case management clinical algorithms for the care of a young infant aged up to 2 months.
Each of these parts contains IMCI charts corresponding to the main steps of the IMCI case management process.
more
With this World Health Day, WHO is drawing attention to a group of diseases that are spread by insects and other vectors, the heavy health and economic burdens they impose, and what needs to be done to reduce these burdens. Many of these diseases have been historically confined to distinct geographi...cal areas, but this situation has become more fluid due to a host of ills, including climate change, intensive farming, dams, irrigation, deforestation, population movements, rapid unplanned urbanization, and phenomenal increases in international travel and trade. The control of vector-borne diseases can make a major contribution to poverty reduction, as it precisely targets the poor
more
Namibia guideline for submission of applications for registration of pharmaceuticals for human use in common technical document format.